Only fly in that ointment is if the ACT price upon close of deal is less that 265.
Millennium Healthcare (MHCC) just reported its Sep quarter revenues at $6.3 million versus $489,000, a 1,200% increase.
Because Millennium’s diagnostics are preventive, FDA approved, reimbursable and cost patients little to nothing, and because they add significant income for physicians, sales are beginning to increase exponentially.
Millennium’s gross margins are exceptionally high as the equipment and associated costs typically pays for themselves in the first 30 days of installation.
Millennium’s network is growing dramatically.
$6.3 million was achieved with only a small number of Millennium’s the current 1,300 physician offices.
There are over 30,000 primary care offices.
Millennium has the potential to sign a large number of the 30,000 plus offices.
At 40 cents, Millennium shares are a ground floor opportunity.
Shares are exceptionally cheap today because the company has paid many professional fees with shares of stock that have depressed shares prices because they have been sold over the past several months.
Invest a few minutes of your time to read the 10Q for yourself and confirm an exceptional opportunity.
MHCC is a very strong buy!
Sentiment: Strong Buy
Or something else. The truth is, Pyott is a man who turned AGN around from a failing eye care little enterprise into a super organic growth powerhouse within the pharma and med device industry. He is a champion finally ending up achieving 66bn for his company and as a testament to his prowess, the company paying that 66bn has seen its share price rocket on foot of the acquisition announcement.
Is that the legacy of a naive man? Perhaps he had particular reasons to sell at that time regardless of the price. Truth is, no one on this board knows for sure. But look at the facts rather than the conjecture and stop making idiot remarks. It's not actually Pyott you are showing up.
Way overpriced, if Pyott dumped at $123. he was very naïve, or he knew what the value of the shares were worth. He should thank Pearson for creating the financial wind fall AGN shareholders are enjoying.
Better lay off the wacky tobaccy! It is only thanks to VRX that AGN isn't languishing under $150.00!
Dear gthcgd, can we please have our message board back? Everyone wins blah blah
Arbs and the market is more heavily interested in owning the combined company which is why ACT is rocketing. Buying allergan will only yield .386 of the combined company
This delta b/w the current price and $219 has to do with "uncertainties" of the deal. The deal won't close until April 2015. Although very certain, it is not a done deal. It is also the reason why Allergan stock is not moving up relative to Actavis. Ex-uncertainties, Allergan stock should be $129+(269.6*0.3683) = $228.29.